Drugs / Osimertinib
Regulatory milestones approvals, filings & regulatory actions · 10 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (8) | US (FDA) | TAGRISSO | — | 2017-03-30 – 2024-09-25 | fda.gov ↗ |
| Approved | EU (EMA) | Tagrisso | — | 2016-02-01 | europa.eu ↗ |
| Approved | US (FDA) | TAGRISSO | — | 2015-11-13 | fda.gov ↗ |
Trials 225 · started per year
today
US approved 2015
EU approved 2016
2
14
12
14
10
23
17
17
24
18
13
26
14
20
2013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07458919 | Mar 2026 → Oct 2030 expected | lung cancer | Fuzhou General Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06557096 | Aug 2024 → Jun 2027 expected | non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT04135807 | Mar 2020 → Jan 2028 expected | anaplastic astrocytoma, anaplastic oligodendroglioma, brain oligodendroglioma, glioblastoma | Oliver Jonas | Recruiting | No outcome recorded |
| Phase 0 | NCT03755102 | Nov 2018 → Jul 2023 | lung cancer | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 144 trials | ||||||
| Phase 1 | NCT07361705 | Jan 2026 → Apr 2028 expected | — | Alpha Biopharma (Jiangsu) Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT07315113 | Dec 2025 → Dec 2026 expected | lung cancer | Nuvectis Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06507306 | Jun 2024 → Jul 2026 overdue | cancer | Kumquat Biosciences Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT06362980 | May 2024 → Apr 2025 overdue | non-small cell lung carcinoma | National Cancer Center, China | Recruiting | No outcome recorded |
| Phase 1 | NCT05954871 | Jan 2024 → Sep 2025 | colorectal cancer, non-small cell lung carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06067776 | Jan 2024 → Jan 2025 overdue | non-small cell lung carcinoma | Jonathan Riess | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05401110 | Sep 2023 → Jan 2028 expected | non-small cell lung carcinoma | Karen Reckamp, MD, MS | Recruiting | No outcome recorded |
| Phase 1 | NCT06032936 | Jul 2023 → Mar 2024 | non-small cell lung carcinoma | LianBio LLC | Terminated | No outcome recorded |
| Phase 1 | NCT05120960 | Feb 2023 → Apr 2024 | brain neoplasm | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1 | NCT05693090 | Feb 2023 → Jul 2027 | non-small cell lung carcinoma | Kura Oncology, Inc. | Withdrawn | No outcome recorded |
| Phase 1 | NCT04772235 | Feb 2022 → Apr 2026 | non-small cell lung carcinoma | Instituto Oncológico Dr Rosell | Unknown | No outcome recorded |
| Phase 1 | NCT04780568 | Jan 2022 → Jul 2026 overdue | non-small cell lung carcinoma | Ohio State University Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT05228015 | Jan 2022 → Aug 2024 | epithelioid hemangioendothelioma, malignant pleural mesothelioma | Ikena Oncology | Terminated | No outcome recorded |
| Phase 1 | NCT04959981 | Sep 2021 → Apr 2023 | non-small cell lung carcinoma | Erasca, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04862780 | Jun 2021 → Oct 2024 | adenocarcinoma, bronchogenic carcinoma, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT04676477 | Jun 2021 → Jan 2025 overdue | non-small cell lung carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04798638 | Apr → Sep 2021 | — | TYK Medicines, Inc | Completed | No outcome recorded |
| Phase 1 | NCT04762199 | Feb 2021 → Dec 2026 expected | non-small cell lung carcinoma | Emory University | Recruiting | No outcome recorded |
| Phase 1 | NCT04721015 | Feb 2021 → Feb 2026 overdue | non-small cell lung carcinoma | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04541407 | Oct 2020 → Apr 2022 | non-small cell lung carcinoma | University of Colorado, Denver | Completed | No outcome recorded |
| Phase 1 | NCT04141644 | Aug 2020 → Jan 2024 overdue | non-small cell lung carcinoma | University of Utah | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04001777 | Jul 2019 → Dec 2025 overdue | non-small cell lung carcinoma | Ascentage Pharma Group Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03891615 | Jun 2019 → Apr 2022 | lung cancer | Massachusetts General Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03810807 | Jan 2019 → Dec 2025 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03535363 | Oct 2018 → Apr 2022 | non-small cell lung carcinoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03567642 | Jun 2018 → Jun 2027 expected | lung cancer | Memorial Sloan Kettering Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02923947 | May 2017 → Sep 2018 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02908750 | Mar → Jul 2017 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02520778 | Aug 2016 → Oct 2022 | non-small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT02496663 | May 2016 → Jun 2027 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02529995 | Aug 2015 → Jan 2016 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02491944 | Jul → Aug 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02317016 | Mar → Jul 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02161770 | Dec 2014 → May 2017 | cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02197234 | Dec 2014 → Apr 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02197247 | Dec 2014 → Jul 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02163733 | Nov 2014 → Mar 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02157883 | Nov 2014 → Apr 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02228369 | Nov 2014 → Aug 2017 | lung cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02224053 | Sep 2014 → Jan 2015 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02143466 | Aug 2014 → Mar 2020 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02096679 | May → Aug 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT02099058 | Jan 2014 → Aug 2026 overdue | — | AbbVie | Active not recruiting | No outcome recorded |
| Phase 1 | NCT01951599 | Oct 2013 → Jun 2014 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1/227 trials | ||||||
| Phase 1/2 | NCT07153055 | Aug 2026 → Apr 2029 expected | small cell lung carcinoma | Misty Shields | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07612137 | Jun 2026 → Jun 2027 expected | cancer | Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07486648 | May 2026 → Oct 2028 expected | non-small cell lung carcinoma | Shanxi Province Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07535437 | Apr 2026 → Apr 2028 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07206498 | Oct 2025 → Oct 2028 expected | non-small cell lung carcinoma | Wayshine Biopharm, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06618287 | Feb 2025 → Feb 2031 expected | breast cancer, lung cancer | Bristol-Myers Squibb | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06306456 | Mar 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Suzhou Genhouse Bio Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06071013 | Feb 2024 → Aug 2026 overdue | non-small cell lung carcinoma | China Medical University Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05785741 | Aug 2023 → Dec 2027 expected | neoplasm | DualityBio Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05498389 | Jun 2023 → Jul 2024 | non-small cell lung carcinoma | Shanghai EpimAb Biotherapeutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05284994 | Mar 2022 → Apr 2024 | non-small cell lung carcinoma | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05017025 | Feb 2022 → Jun 2028 expected | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04486833 | Sep 2021 → Mar 2028 expected | non-small cell lung carcinoma | Genprex, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04868877 | Apr 2021 → Mar 2026 overdue | colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, head and neck squamous cell carcinoma +1 | Merus B.V. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04720976 | Mar 2021 → Dec 2023 | non-small cell lung carcinoma | Allist Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04285671 | Jan 2021 → Dec 2026 expected | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04770688 | Nov 2020 → Jun 2024 | lung adenocarcinoma, metastatic malignant neoplasm | Shanghai Chest Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT03831932 | Mar 2020 → Jun 2024 overdue | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03989115 | Jul 2019 → Feb 2022 | cancer | Revolution Medicines, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03381274 | May 2018 → May 2021 overdue | non-small cell lung carcinoma | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03450330 | Apr 2018 → Sep 2019 | non-small cell lung carcinoma | Dizal Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT03455829 | Mar 2018 → Dec 2021 | non-small cell lung carcinoma | G1 Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03122717 | May 2017 → Oct 2026 expected | non-small cell lung carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02917993 | Dec 2016 → Dec 2025 | lung cancer | Incyte Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT02954523 | Oct 2016 → Aug 2018 | non-small cell lung carcinoma | Chul Kim | Terminated | No outcome recorded |
| Phase 1/2 | NCT02803203 | Jun 2016 → Mar 2022 | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01802632 | Mar 2013 → May 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2105 trials | ||||||
| Phase 2 | NCT07622186 | Jul 2026 → Dec 2028 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07669779 | Jul 2026 → Aug 2027 expected | non-small cell lung carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT07603791 | Jun 2026 → Dec 2027 expected | non-small cell lung carcinoma | Shanghai Allink Biotherapeutics Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07485452 | Jun 2026 → Jun 2027 expected | non-small cell lung carcinoma | Maastricht University Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07637448 | May 2026 → Mar 2029 expected | non-small cell lung carcinoma | Nanfang Hospital, Southern Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT07295821 | Apr 2026 → May 2029 expected | lung cancer | AstraZeneca | Recruiting | No outcome recorded |
| Phase 2 | NCT07329322 | Mar 2026 → Aug 2027 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07323641 | Feb 2026 → Feb 2027 expected | non-small cell lung carcinoma | Jonsson Comprehensive Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT07505173 | Jan 2026 → Jan 2028 expected | — | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07375316 | Dec 2025 → Jun 2028 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Recruiting | No outcome recorded |
| Phase 2 | NCT07256509 | Nov 2025 → Nov 2026 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07058519 | Sep 2025 → Jan 2029 expected | non-small cell lung carcinoma | Shanghai Chest Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT07177092 | Sep 2025 → Oct 2028 expected | EGF-related primary hypomagnesemia with intellectual disability, non-small cell lung carcinoma | Jianxing He | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06630325 | Jun 2025 → Mar 2026 | exocrine pancreatic carcinoma, female breast carcinoma, ovarian carcinoma, prostate carcinoma +1 | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT06918782 | May 2025 → Dec 2027 expected | non-small cell lung carcinoma | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06692491 | Jan 2025 → Dec 2027 expected | — | Peking University Shenzhen Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07322783 | Jan 2025 → Dec 2026 expected | non-small cell lung carcinoma | Qingdao Central Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06741085 | Dec 2024 → Dec 2027 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06827145 | Oct 2024 → Sep 2026 expected | non-small cell lung carcinoma | National Cancer Center, China | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06498986 | Jul 2024 → Aug 2026 overdue | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06530719 | Jul 2024 → May 2026 overdue | non-small cell lung carcinoma | Jin Ying | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06436144 | Jun 2024 → Jun 2029 expected | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06194448 | Apr 2024 → Jul 2026 overdue | lung cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06363734 | Apr 2024 → Dec 2025 overdue | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06383728 | Apr 2024 → Oct 2025 overdue | squamous cell lung carcinoma | The First Affiliated Hospital of Guangzhou Medical University | Recruiting | No outcome recorded |
| Phase 2 | NCT06206850 | Feb 2024 → Jan 2029 expected | non-small cell lung carcinoma | Jair Bar, M.D., Ph.D. | Recruiting | No outcome recorded |
| Phase 2 | NCT06185400 | Feb 2024 → Jul 2025 overdue | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06142617 | Dec 2023 → Nov 2027 expected | non-small cell lung carcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06018688 | Sep 2023 → Mar 2026 overdue | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05773092 | Aug 2023 → Oct 2025 overdue | non-small cell lung carcinoma | National Cancer Centre, Singapore | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05801029 | Jul 2023 → Oct 2027 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05526755 | Mar 2023 → Nov 2029 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05546866 | Feb 2023 → Jun 2029 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05686434 | Oct 2022 → Oct 2024 overdue | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05536505 | Sep 2022 → Oct 2025 overdue | — | Guangdong Association of Clinical Trials | Recruiting | No outcome recorded |
| Phase 2 | NCT05528458 | Sep 2022 → Sep 2027 expected | lung adenocarcinoma | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04908956 | Aug 2022 → Oct 2023 | non-small cell lung carcinoma | ETOP IBCSG Partners Foundation | Terminated | No outcome recorded |
| Phase 2 | NCT05085054 | Jun 2022 → May 2024 | non-small cell lung carcinoma | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
| Phase 2 | NCT05163249 | May 2022 → Apr 2024 overdue | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05089916 | Jan 2022 → Mar 2026 overdue | non-small cell lung carcinoma | AIO-Studien-gGmbH | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05215951 | Jan 2022 → Mar 2023 | lung cancer | AstraZeneca | Terminated | No outcome recorded |
| Phase 2 | NCT05298176 | Jan 2022 → Apr 2024 | non-small cell lung carcinoma | Amsterdam UMC, location VUmc | Completed | No outcome recorded |
| Phase 2 | NCT04769388 | Dec 2021 → Dec 2026 expected | non-small cell lung carcinoma | Beijing Cancer Prevention & Treatment Society | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06391944 | Nov 2021 → May 2023 overdue | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05132777 | Nov 2021 → Sep 2023 | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT05281406 | Nov 2021 → Nov 2025 overdue | non-small cell lung carcinoma | Goethe University | Recruiting | No outcome recorded |
| Phase 2 | NCT05011487 | Aug 2021 → Sep 2023 overdue | non-small cell lung carcinoma | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 2 | NCT05507606 | Aug 2021 → Aug 2023 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04974879 | Jul 2021 → Jul 2024 | non-small cell lung carcinoma | Qingdao Central Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04335292 | Jan 2021 → Jun 2026 overdue | non-small cell lung carcinoma | Mark Vincent | Recruiting | No outcome recorded |
| Phase 2 | NCT04438902 | Dec 2020 → Dec 2022 | non-small cell lung carcinoma | First Affiliated Hospital of Zhejiang University | Terminated | No outcome recorded |
| Phase 2 | NCT04545710 | Nov 2020 → Dec 2025 overdue | lung cancer | University of California, San Diego | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04563871 | Nov 2020 → Oct 2023 | non-small cell lung carcinoma | Samsung Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04606771 | Sep 2020 → Dec 2022 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05458726 | Sep 2020 → Jul 2022 | non-small cell lung carcinoma | Peking Union Medical College | Unknown | No outcome recorded |
| Phase 2 | NCT04233021 | Jul 2020 → Mar 2023 | metastatic malignant neoplasm in the brain, neoplastic meningitis, non-small cell lung carcinoma | French Cooperative Thoracic Intergroup | Completed | No outcome recorded |
| Phase 2 | NCT04811001 | Jun 2020 → Dec 2023 | non-small cell lung carcinoma | Fondazione Ricerca Traslazionale | Unknown | No outcome recorded |
| Phase 2 | NCT04322890 | Apr 2020 → Dec 2026 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04644432 | Mar 2020 → Sep 2022 | renal cell carcinoma | Herlev and Gentofte Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04148898 | Nov 2019 → Mar 2021 | neoplastic meningitis, non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 2 | NCT03940703 | Sep 2019 → May 2023 overdue | non-small cell lung carcinoma | EMD Serono Research & Development Institute, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03497767 | Aug 2019 → Apr 2024 | non-small cell lung carcinoma | Trans Tasman Radiation Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT04029350 | Jul 2019 → Jan 2020 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03944772 | Jun 2019 → May 2025 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03810066 | Jun 2019 → Dec 2021 | non-small cell lung carcinoma | University Hospital, Essen | Completed | No outcome recorded |
| Phase 2 | NCT03865511 | Apr 2019 → Jan 2025 | non-small cell lung carcinoma | Nantes University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT03769103 | Mar 2019 → Apr 2025 overdue | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | British Columbia Cancer Agency | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03778229 | Jan 2019 → Aug 2024 overdue | carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04184921 | Jan 2019 → Jun 2023 | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT03784599 | Dec 2018 → May 2021 | non-small cell lung carcinoma | The Netherlands Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT03804580 | Dec 2018 → Jun 2025 | lung cancer | Vestre Viken Hospital Trust | Unknown | No outcome recorded |
| Phase 2 | NCT03732352 | Nov 2018 → Jan 2024 | RELA fusion-positive ependymoma, glioblastoma | Jonsson Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT02824952 | Nov 2018 → Dec 2022 | non-small cell lung carcinoma | Shaare Zedek Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT03667820 | Sep 2018 → Sep 2027 expected | non-small cell lung carcinoma | University of Texas Southwestern Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03586453 | Aug 2018 → Feb 2028 expected | non-small cell lung carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03433469 | Jul 2018 → Jan 2023 overdue | non-small cell lung carcinoma | University of California, San Francisco | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03434418 | Jun 2018 → Oct 2022 | non-small cell lung carcinoma | Duke University | Completed | No outcome recorded |
| Phase 2 | NCT02971501 | Jun 2018 → Feb 2025 overdue | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03239340 | May 2018 → Sep 2023 | lung cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT03191149 | Apr 2018 → Jun 2027 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT03460275 | Feb 2018 → Dec 2020 | non-small cell lung carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT03392246 | Jan 2018 → Jun 2026 overdue | non-small cell lung carcinoma | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03410043 | Jan 2018 → Apr 2027 expected | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03414814 | Jan 2018 → Aug 2021 | — | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT03543683 | Jan 2018 → Jan 2023 | non-small cell lung carcinoma | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | Completed | No outcome recorded |
| Phase 2 | NCT02856893 | Oct 2017 → Sep 2022 | non-small cell lung carcinoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 2 | NCT04425681 | Oct 2017 → Jul 2020 | malignant leptomeningeal tumor, non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Unknown | No outcome recorded |
| Phase 2 | NCT03040973 | Aug 2017 → Jul 2027 expected | — | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03394118 | Aug 2017 → Mar 2021 | non-small cell lung carcinoma | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03133546 | May 2017 → Feb 2021 | non-small cell lung carcinoma | ETOP IBCSG Partners Foundation | Completed | No outcome recorded |
| Phase 2 | NCT03257124 | May 2017 → Aug 2019 | lung cancer, metastatic malignant neoplasm in the brain | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02811354 | Feb 2017 → Feb 2019 | non-small cell lung carcinoma | National University Hospital, Singapore | Unknown | No outcome recorded |
| Phase 2 | NCT02841579 | Sep 2016 → Dec 2018 | non-small cell lung carcinoma | MedSIR | Completed | No outcome recorded |
| Phase 2 | NCT02771314 | Aug 2016 → Jun 2020 | non-small cell lung carcinoma | Hellenic Oncology Research Group | Unknown | No outcome recorded |
| Phase 2 | NCT02769286 | Aug 2016 → Dec 2018 | lung neoplasm | Chonnam National University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT02736513 | May 2016 → Dec 2022 | lung cancer | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02759835 | Apr 2016 → May 2022 | lung adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT06303167 | Jan 2016 → Feb 2023 overdue | plasma cell myeloma, refractory malignant neoplasm | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03424759 | Jan 2016 → Dec 2017 | non-small cell lung carcinoma | Samsung Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT02465060 | Aug 2015 → Dec 2026 expected | breast carcinoma, carcinoma of esophagus, cervical carcinoma, colon carcinoma +17 | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02504346 | Aug 2015 → Jun 2023 | lung cancer | Oslo University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT02442349 | Jun 2015 → Mar 2016 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT02664935 | May 2015 → Nov 2023 | adenocarcinoma, non-small cell lung carcinoma, squamous cell carcinoma | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT02179671 | Jul 2014 → Jun 2016 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT02094261 | May 2014 → May 2015 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 2/35 trials | ||||||
| Phase 2/3 | NCT07642024 | Jun 2026 → Dec 2032 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07155187 | Dec 2025 → Sep 2030 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06908772 | Apr 2025 → Dec 2028 expected | — | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05020769 | Jan 2022 → Dec 2025 overdue | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT02959749 | Aug 2015 → Oct 2017 | — | Qingdao Central Hospital | Completed | No outcome recorded |
| Phase 330 trials | ||||||
| Phase 3 | NCT07680790 | Sep 2026 → Dec 2031 expected | non-small cell lung carcinoma | Bristol-Myers Squibb | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07640789 | Jun 2026 → Dec 2030 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06829459 | Apr 2025 → Feb 2028 expected | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06670196 | Nov 2024 → May 2027 expected | non-small cell lung carcinoma | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06735391 | Oct 2024 → Sep 2026 expected | — | Shanghai JMT-Bio Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06417814 | Oct 2024 → Sep 2026 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06093503 | May 2024 → Apr 2028 | non-small cell lung carcinoma | AbbVie | Withdrawn | No outcome recorded |
| Phase 3 | NCT06350097 | Apr 2024 → Mar 2028 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 3 | NCT06380348 | Apr 2024 → Mar 2027 expected | non-small cell lung carcinoma | Shanghai JMT-Bio Inc. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06323148 | Apr 2024 → Mar 2026 overdue | lung cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05629234 | May 2023 → Feb 2027 expected | cancer | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05261399 | Aug 2022 → Jun 2026 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05120349 | Feb 2022 → Aug 2027 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05015608 | Nov 2021 → Aug 2025 | non-small cell lung carcinoma | Hutchison Medipharma Limited | Completed | No outcome recorded |
| Phase 3 | NCT04816214 | Sep 2021 → Dec 2022 | non-small cell lung carcinoma | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04765059 | Sep 2021 → Oct 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04695925 | Mar 2021 → Nov 2025 overdue | non-small cell lung carcinoma | Li Zhang, MD | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05104281 | Jan 2021 → Dec 2023 | non-small cell lung carcinoma | Qingdao Central Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04181060 | Dec 2020 → Dec 2026 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 3 | NCT04351555 | Dec 2020 → Oct 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03833154 | Mar 2019 → Oct 2028 expected | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03521154 | Jul 2018 → Jan 2024 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02997501 | Dec 2016 → Oct 2018 | lung cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02972333 | Dec 2016 → Sep 2019 | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | Shandong Cancer Hospital and Institute | Unknown | No outcome recorded |
| Phase 3 | NCT02511106 | Oct 2015 → Apr 2022 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02474355 | Sep 2015 → Apr 2019 | lung cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02454933 | Jul 2015 → Aug 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02411448 | May 2015 → Jan 2019 overdue | non-small cell lung carcinoma | Eli Lilly and Company | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02296125 | Dec 2014 → Jun 2017 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 3 | NCT02151981 | Aug 2014 → Apr 2016 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT07279935 | May 2026 → May 2030 expected | non-small cell lung carcinoma | AstraZeneca | Recruiting | No outcome recorded |
| Phase 4 | NCT05785208 | Jun 2022 → Feb 2024 | non-small cell lung carcinoma | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Unknown | No outcome recorded |
| Phase 4 | NCT04413201 | Sep 2020 → Dec 2026 expected | non-small cell lung carcinoma | Michael Hopp | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03853551 | Apr 2019 → Apr 2020 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT07398599 | Feb 2026 → Dec 2027 expected | malignant leptomeningeal tumor, non-small cell lung carcinoma | Second Affiliated Hospital of Nanchang University | Recruiting | No outcome recorded |
| — | NCT06709274 | Nov 2024 → Jan 2029 expected | non-small cell lung carcinoma | Guangdong Association of Clinical Trials | Not yet recruiting | No outcome recorded |
| — | NCT06304441 | Apr 2024 → Jun 2026 overdue | neoplastic meningitis | Guangzhou Medical University | Recruiting | No outcome recorded |
| — | NCT04816838 | May 2021 → Jul 2025 | non-small cell lung carcinoma | Yonsei University | Unknown | No outcome recorded |
| — | NCT03969823 | May 2019 → Sep 2026 expected | — | Seoul National University Hospital | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT02451852 | — | — | AstraZeneca | No longer available | No outcome recorded |
Also used as a comparator or background therapy in 58 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 116 trials | ||||||
| Phase 1 | NCT06218940 Background | Dec 2024 → Dec 2026 expected | non-small cell lung carcinoma | Newsoara Biopharma Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT05647122 Background | Dec 2022 → Aug 2028 expected | colorectal neoplasm, head and neck neoplasm, non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05489731 Background | Sep 2022 → Feb 2024 | non-small cell lung carcinoma | Jiesi Yingda Pharmaceutical Technology (Suzhou) Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05142189 Background | Jun 2022 → Feb 2030 expected | non-small cell lung carcinoma | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1 | NCT05166616 Background | Mar 2022 → Oct 2027 expected | non-small cell lung carcinoma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05153408 Background | Jan → Dec 2022 | adenocarcinoma, bronchogenic carcinoma, non-small cell lung carcinoma | Blueprint Medicines Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT06525246 Background | Aug 2021 → Jun 2025 | non-small cell lung carcinoma | Ono Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT04479306 Background | Jun 2020 → Jul 2023 | non-small cell lung carcinoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT04085315 Background | Nov 2019 → Dec 2026 expected | lung cancer | Collin Blakely | Recruiting | No outcome recorded |
| Phase 1 | NCT03255083 Background | Apr 2019 → Sep 2020 | non-small cell lung carcinoma | Daiichi Sankyo | Terminated | No outcome recorded |
| Phase 1 | NCT03463525 Background | Oct 2018 → Mar 2020 | non-small cell lung carcinoma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT07271446 Background | Sep 2018 → Aug 2019 | non-small cell lung carcinoma | Precision Biotech Taiwan Corp. | Completed | No outcome recorded |
| Phase 1 | NCT03418532 Background | Mar 2018 → Aug 2019 | non-small cell lung carcinoma | Molecular Partners AG | Terminated | No outcome recorded |
| Phase 1 | NCT02503722 Background | Mar 2017 → Feb 2027 expected | non-small cell lung carcinoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02789345 Background | Oct 2016 → Oct 2017 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT03050411 Background | May 2016 → Jun 2019 | non-small cell lung carcinoma | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT07285148 Comparator | Jun 2026 → Dec 2029 expected | non-small cell lung carcinoma | Beijing Pearl Biotechnology Limited Liability Company | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07079475 Comparator | Jul 2025 → Jun 2028 expected | non-small cell lung carcinoma | Dizal Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06109558 Background | Dec 2023 → Dec 2026 expected | non-small cell lung carcinoma | Hunan Province Tumor Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04743505 Background | Jan 2022 → Jan 2027 expected | non-small cell lung carcinoma | Washington University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04665206 Background | Mar 2021 → Nov 2029 expected | mesothelioma, non-small cell lung carcinoma | Vivace Therapeutics, Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03799094 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Clifford Hospital, Guangzhou, China | Unknown | No outcome recorded |
| Phase 220 trials | ||||||
| Phase 2 | NCT07710612 Background | Aug 2026 → Dec 2029 expected | non-small cell lung carcinoma | Abbisko Therapeutics Co, Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07379476 Comparator | Feb 2026 → Mar 2029 expected | non-small cell lung carcinoma | Chinese University of Hong Kong | Recruiting | No outcome recorded |
| Phase 2 | NCT07229729 Comparator | Nov 2025 → Oct 2026 expected | non-small cell lung carcinoma | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT07038460 Background | Jul 2025 → Dec 2027 expected | non-small cell lung carcinoma | Wen-zhao ZHONG | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06895928 Background | Mar 2025 → Dec 2028 expected | cancer | Shanghai Hengrui Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06752408 Comparator | Dec 2024 → Jan 2027 expected | non-small cell lung carcinoma | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06014827 Background | Oct 2024 → Jul 2026 overdue | non-small cell lung carcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06574347 Comparator | Aug 2024 → Oct 2026 expected | non-small cell lung carcinoma | Avistone Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT06452433 Background | Jun 2024 → Dec 2027 expected | non-small cell lung carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06319950 Comparator | Apr 2024 → Dec 2026 expected | non-small cell lung carcinoma | Taizhou Hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05948813 Comparator | Aug 2023 → Jun 2025 overdue | metastatic malignant neoplasm in the brain, non-small cell lung carcinoma | TYK Medicines, Inc | Recruiting | No outcome recorded |
| Phase 2 | NCT05880706 Background | Jul 2023 → Jul 2027 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05642572 Background | May 2023 → Jun 2027 expected | non-small cell lung carcinoma | SWOG Cancer Research Network | Recruiting | No outcome recorded |
| Phase 2 | NCT05816252 Background | Apr 2023 → Jun 2026 overdue | non-small cell lung carcinoma | Klus Pharma Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04591002 Comparator | Sep 2022 → Sep 2027 expected | lung cancer | Samsung Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT04988607 Comparator | Aug 2021 → Nov 2024 | lung cancer | Guangdong Association of Clinical Trials | Unknown | No outcome recorded |
| Phase 2 | NCT04829019 Comparator | Apr 2021 → Apr 2024 | cognitive disorder | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 2 | NCT04764214 Background | Mar 2021 → Mar 2023 | non-small cell lung carcinoma | Fudan University | Completed | No outcome recorded |
| Phase 2 | NCT04410796 Background | May 2020 → May 2027 expected | non-small cell lung carcinoma | Memorial Sloan Kettering Cancer Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03909334 Comparator | Jul 2019 → Dec 2026 expected | metastatic malignant neoplasm, non-small cell lung carcinoma | Xiuning Le | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07005102 Background | Aug 2025 → Dec 2031 expected | non-small cell lung carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 311 trials | ||||||
| Phase 3 | NCT07376382 Background | Jun → Dec 2026 expected | non-small cell lung carcinoma | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07185997 Comparator | Dec 2025 → Feb 2029 expected | non-small cell lung carcinoma | ArriVent BioPharma, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06838273 Comparator | Feb 2025 → Dec 2028 expected | non-small cell lung carcinoma | Sichuan Baili Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT06970639 Comparator | Sep 2024 → Mar 2029 expected | — | Allist Pharmaceuticals, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT05624996 Background | Jul 2023 → Oct 2031 expected | non-small cell lung carcinoma | NRG Oncology | Recruiting | No outcome recorded |
| Phase 3 | NCT05493501 Comparator | Dec 2022 → Aug 2023 | non-small cell lung carcinoma | EQRx International, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT06486142 Comparator | Sep 2022 → Sep 2028 expected | non-small cell lung carcinoma | Region Skane | Recruiting | No outcome recorded |
| Phase 3 | NCT05382728 Comparator | Jun 2022 → May 2025 overdue | non-small cell lung carcinoma | TYK Medicines, Inc | Recruiting | No outcome recorded |
| Phase 3 | NCT04870190 Comparator | Jun 2021 → Jun 2024 | non-small cell lung carcinoma | Shanghai Chest Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT04487080 Comparator | Sep 2020 → Aug 2023 overdue | non-small cell lung carcinoma | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04035486 Comparator | Jul 2019 → Apr 2023 overdue | non-small cell lung carcinoma | AstraZeneca | Active not recruiting | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT06824792 Background | Mar 2025 → Feb 2028 expected | cancer | NING LI | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT04401059 Comparator | Nov 2020 → Sep 2025 | adenocarcinoma, non-small cell lung carcinoma | Tian Xie | Unknown | No outcome recorded |
| Phase 4 | NCT04356118 Background | Jun 2020 → Jun 2023 | malignant leptomeningeal tumor | Hui Bu | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05583409 Comparator | Jan 2023 → Dec 2024 | non-small cell lung carcinoma | Li Zhang | Unknown | No outcome recorded |
Press releases naming this drug 16 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-07 | AstraZeneca | Tagrisso plus chemotherapy demonstrated a median overall survival of nearly four years, the longest benefit ever reported in a global Phase III trial in EGFR-mutated advanced lung cancer astrazeneca.com ↗ |
| 2025-07-21 | AstraZeneca | Tagrisso plus chemotherapy demonstrated statistically significant and clinically meaningful improvement in overall survival in EGFR-mutated advanced lung cancer astrazeneca.com ↗ |
| 2025-03-25 | AstraZeneca | New study results reinforce Tagrisso as the backbone therapy for EGFR-mutated lung cancer across stages and settings astrazeneca.com ↗ |
| 2024-12-23 | AstraZeneca | Tagrisso approved in the EU for patients with unresectable EGFR-mutated lung cancer astrazeneca.com ↗ |
| 2024-11-18 | AstraZeneca | Tagrisso recommended for approval in the EU by CHMP for patients with unresectable EGFR-mutated lung cancer astrazeneca.com ↗ |
| 2024-09-26 | AstraZeneca | Tagrisso approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer astrazeneca.com ↗ |
| 2024-07-05 | AstraZeneca | Tagrisso with the addition of chemotherapy approved in the EU as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer astrazeneca.com ↗ |
| 2024-06-26 | AstraZeneca | Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer astrazeneca.com ↗ |
| 2024-06-25 | AstraZeneca | Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer astrazeneca.com ↗ |
| 2024-06-10 | AstraZeneca | Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer astrazeneca.com ↗ |
| 2024-06-03 | AstraZeneca | Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer astrazeneca.com ↗ |
| 2024-06-02 | AstraZeneca | Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial astrazeneca.com ↗ |
| 2024-03-21 | AstraZeneca | Tagrisso with the addition of chemotherapy showed favourable trend in overall survival in EGFR-mutated advanced lung cancer with further follow up in FLAURA2 Phase III trial astrazeneca.com ↗ |
| 2024-02-19 | AstraZeneca | Tagrisso with the addition of chemotherapy approved in the US for patients with EGFR-mutated advanced lung cancer astrazeneca.com ↗ |
| 2024-02-19 | AstraZeneca | Tagrisso demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial astrazeneca.com ↗ |
| 2020-08-07 | Daiichi Sankyo | Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan (U3-1402) in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer daiichisankyo.com ↗ |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 292 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | osimertinib | “OBJECTIVES: Reliable epidermal growth factor receptor (EGFR) mutation testing techniques are required to identify eligible patients with EGFR mutation/T790M positive advanced...” PMID 28577957 ↗ Apr 2017258“AZD9291 (osimertinib) is a potent irreversible inhibitor of both the single epidermal growth factor receptor sensitising mutation positive (EGFRm+) (tyrosine kinase inhibitor...” NCT02143466 ↗ “The microdevices will dwell in the tumor tissue for a time window of 2-4 hours to allow time for tissue effects of the drugs (Temozolomide, Lomustine, Irinotecan, Carboplatin,...” NCT04135807 ↗ “A phase I/II, open-label, multicentre study to investigate the safety, tolerability, pharmacokinetics and anti-tumour activity of AZD4205 as monotherapy or in combination with...” NCT03450330 ↗ “Osimertinib is a potent, third-generation, irreversible, central nervous system active epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that selectively...” PMID 30875094 ↗ Mar 2019 “Osimertinib is a third-generation, central nervous system-active, epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) selective for EGFR-TKI sensitizing and...” PMID 29683562 ↗ Apr 2018 “Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met...” PMID 27751847 ↗ Oct 2016 “Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC.” PMID 34723634 ↗ Nov 2021 “All patients receive first-line oral therapy with standard-dose third-generation EGFR-TKIs (osimertinib, aumolertinib, or furmonertinib).” NCT07637448 ↗ “Osimertinib, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI), undergoes significant hepatic elimination.” PMID 30872388 ↗ Mar 2019 “Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)” PMID 29151359 ↗ Nov 2017 “Patients in the combination therapy portion of this study will receive osimertinib administered once daily (QD) with HY1272.” NCT06218940 ↗ “Gefitinib(Iressa,YiRuiKe), Erlotinib(Tarceva), Icotinib(Kaimeina), Osimertinib(Tagrisso), Almonertinib, Furmonertinib, etc.” NCT04401059 ↗ “75 patients received tyrosine kinase inhibitor daily. (dose: Osimertinib 80 mg/d, or Tarceva 150 mg/d, or Iressa 0.25 g/d.)” NCT03799094 ↗ “If EGFR T790M mutation was found, researchers would resume medication and choose osimertinib therapy.” NCT05536505 ↗ “Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin.” PMID 30171779 ↗ Oct 2018 “osimertinib 80 mg oral, daily tablet OR afatinib 40 mg oral, daily tablet” NCT07185997 ↗ “Osimertinib will be administered orally at the dose of 80 mg once daily.” NCT04764214 ↗ “Osimertinib 80mg once daily until disease progression” NCT03969823 ↗ “Osimertinib, 80mg, continuously for 28 days” NCT06109558 ↗ “Osimertinib 80 mg once a day for 4 weeks.” NCT04644432 ↗ “Osimertinib (80 mg, orally, once daily)” NCT02151981 ↗ “Osimertinib: 80 mg per dose, once daily” NCT07458919 ↗ “Osimertinib 160mg once po everyday” NCT06380348 ↗ “oral osimertinib 160mg once daily” NCT07398599 ↗ “Erlotinib，Afatinib，Osimertinib” NCT04356118 ↗ |
| Known as | AZD9291 | “AZD9291 (osimertinib) is a potent irreversible inhibitor of both the single epidermal growth factor receptor sensitising mutation positive (EGFRm+) (tyrosine kinase inhibitor...” NCT02143466 ↗35“Osimertinib (AZD9291) is an oral, potent, irreversible EGFR tyrosine-kinase inhibitor selective for EGFR tyrosine-kinase inhibitor sensitising mutations, and the EGFR Thr790Met...” PMID 27751847 ↗ Oct 2016 “Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation.” NCT04184921 ↗ “Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation.” NCT03543683 ↗ “Osimertinib (AZD9291) is a novel oral, potent, and selective third-generation irreversible inhibitor of both EGFRm-sensitizing and T790M resistance mutants.” NCT03133546 ↗ “Osimertinib, (AZD9291, Tagrisso, AstraZeneca) is a third-generation EGFRTKI” NCT04811001 ↗ “AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy” NCT02151981 ↗ “Osimertinib (AZD9291) pemetrexed cisplatin or carboplatin” NCT04765059 ↗ “osimertinib (AZD9291) and bevacizumab” NCT04181060 ↗ “Osimertinib; AZD9291” NCT02923947 ↗ |
| Known as | Osi | “fixed dose of osimertinib (Osi)” NCT07005102 ↗ |
| Known as | Osimertinib Mesylate | “osimertinib mesylate tablets 80mg qd and anlotinib hydrochloride capsules 10mg qd day 1-14 of a 21-day cycle” NCT04438902 ↗6“Osimertinib mesylate is a third-generation epidermal growth factor receptor inhibitor.” NCT05284994 ↗ “Study Drug: Osimertinib mesylate tablets (Tagrisso®).” NCT07505173 ↗ “Generic name: Osimertinib mesylate” NCT06530719 ↗ “Osimertinib mesylate tablets.” NCT06895928 ↗ “Osimertinib Mesylate Tablets” NCT06908772 ↗ “Osimertinib Mesylate Tablets” NCT06970639 ↗ |
| Known as | Osimertinib Mesylate Tablets | “Drug: Osimertinib Mesylate Tablets” NCT05132777 ↗ |
| Known as | Tagrisso | “Purpose: The mechanisms accounting for anticancer activity of AZD9291 (osimertinib or TAGRISSO), an approved third-generation EGFR inhibitor, in EGFR-mutant non-small cell lung...” PMID 28765329 ↗ Aug 201710“Osimertinib (TAGRISSO®) is a medication used to treat a type of NSCLC with a change (mutation) in the EGFR gene, known as EGFR-mutated NSCLC.” PMID 34723634 ↗ Nov 2021 “Oral administration of TAGRISSO® 80mg (Osimertinib) as a single daily dose until disease progression or unacceptable toxicity.” NCT03865511 ↗ “Osimertinib (TAGRISSO, AZD9291) has been recommended in EGFR-mutant advanced NSCLC patients as first-line treatment.” PMID 36333268 ↗ Sep 2022 “TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy” NCT03394118 ↗ “comparing Tagrisso (osimertinib) with platinum-based chemotherapy” PMID 35575012 ↗ May 2022 “Study Drug: Osimertinib mesylate tablets (Tagrisso®).” NCT07505173 ↗ “Drug: Osimertinib 80 MG [Tagrisso]” NCT03414814 ↗ “Osimertinib (Tagrisso®)” NCT07206498 ↗ |
| Action | Inhibit | “potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M” PMID 31345012 ↗ Jul 2019 |
| Modality | Small molecule | “third-generation, irreversible, oral epidermal growth factor receptor-TKI” PMID 33939068 ↗ May 2021 |
| Route | Oral | “Daily oral dose of AZD9291” NCT01802632 ↗ |
| Target | EGFR | “potently and selectively inhibits both EGFR sensitizing mutation and EGFR T790M” PMID 31345012 ↗ Jul 2019 |